Aspire Biopharma Holdings (ASBP) Operating Income (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has 3 years of Operating Income data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Operating Income rose 89.42% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$20.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$19.4 million, down 1498.13% from the prior year.
• Operating Income for Q1 2026 stood at -$1.6 million, up from -$1.8 million in the prior quarter.
• Over the last five years, Operating Income for ASBP reached as high as -$215256.0 in Q3 2024 and fell as low as -$15.6 million in Q1 2025.
• Historically, Operating Income has averaged -$3.5 million across 3 years, with a median of -$1.4 million in 2025.
• Across the five-year window, Operating Income plunged 432.16% in 2025 and soared 89.42% in 2026, its largest moves.
• Year by year, Operating Income stood at -$667722.0 in 2024, then slumped by 176.98% to -$1.8 million in 2025, then increased by 10.99% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$1.6 million in Q1 2026, -$1.8 million in Q4 2025, and -$1.1 million in Q3 2025.